Strides Pharma Science Ltd
STARStrides Pharma Science Ltd
STAR![](https://assets.tickertape.in/sector-icons/health_care.png)
![](https://assets.tickertape.in/sector-icons/smallcap.png)
![](https://assets.tickertape.in/sector-icons/moderate_risk.png)
Price Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
1,807.98 | 5.56 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
49.93 | 6.39 | 0.52% |
Forecast & Ratings
Detailed Forecast from 3 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Strides Pharma Science is a vertically integrated global pharmaceutical company engaged in the development and manufacturing of active pharmaceutical ingredients and formulations, as well as biotech
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 2,961.59 | 3,097.80 | 3,534.85 | 2,545.66 | 2,909.44 | 3,518.84 | 3,259.23 | 3,935.44 | 4,145.05 | 4,306.63 | ||||||||||
Raw Materials | 1,612.38 | 1,432.25 | 1,286.65 | 1,189.20 | 1,167.29 | 1,686.50 | 1,407.04 | 1,629.55 | 3,672.64 | 3,756.40 | ||||||||||
Power & Fuel Cost | 77.18 | 33.87 | 51.33 | 54.39 | 64.49 | 64.58 | 71.54 | 85.82 | ||||||||||||
Employee Cost | 357.70 | 419.16 | 434.05 | 329.44 | 442.56 | 550.15 | 646.91 | 732.02 | ||||||||||||
Selling & Administrative Expenses | 323.35 | 339.47 | 409.34 | 276.20 | 338.51 | 473.78 | 577.98 | 526.31 | ||||||||||||
Operating & Other expenses | 154.11 | 54.45 | 313.14 | 196.74 | 525.25 | 98.10 | 798.52 | 724.97 | ||||||||||||
EBITDA | 436.87 | 818.60 | 1,040.34 | 499.69 | 371.34 | 645.73 | -242.76 | 236.77 | 472.41 | 550.23 | ||||||||||
Depreciation/Amortization | 131.25 | 126.15 | 154.04 | 117.39 | 173.70 | 206.29 | 233.01 | 243.25 | 220.68 | 209.69 | ||||||||||
PBIT | 305.62 | 692.45 | 886.30 | 382.30 | 197.64 | 439.44 | -475.77 | -6.48 | 251.73 | 340.54 | ||||||||||
Interest & Other Items | 168.17 | 183.10 | 196.24 | 79.29 | 155.72 | 150.07 | 176.74 | 261.14 | 314.45 | 318.42 | ||||||||||
PBT | 137.45 | 509.35 | 690.06 | 303.01 | 41.92 | 289.37 | -652.51 | -267.62 | -62.72 | 22.12 | ||||||||||
Taxes & Other Items | 28.92 | 109.60 | 25.55 | -21.60 | 5.53 | 20.94 | -192.30 | -65.00 | 7.89 | 15.44 | ||||||||||
Net Income | 108.53 | 399.75 | 664.51 | 324.61 | 36.39 | 268.43 | -460.21 | -202.62 | -70.61 | 6.68 | ||||||||||
EPS | 14.10 | 43.28 | 71.89 | 35.67 | 4.06 | 29.95 | -51.29 | -22.50 | -7.76 | 0.74 | ||||||||||
DPS | 4.84 | 4.36 | 1.94 | 3.00 | 14.00 | 2.50 | 0.00 | 1.50 | 0.00 | 1.50 | ||||||||||
Payout ratio | 0.34 | 0.10 | 0.03 | 0.08 | 3.45 | 0.08 | 0.00 | — | 0.00 | 2.03 |
Company Updates
Investor Presentation
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Strides Pharma Science Ltd | -171.04 | 5.56 | — |
Sun Pharmaceutical Industries Ltd | 45.08 | 6.43 | 0.75% |
Cipla Ltd | 31.71 | 4.88 | 0.80% |
Torrent Pharmaceuticals Ltd | 70.18 | 16.95 | 0.82% |
Price Comparison
Compare STAR with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 1.54%
High Pledged Promoter Holding
A significant proportion of promoter holdings is pledged
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 2.14%
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Strides Pharma Science Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Quant Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.7693% | Percentage of the fund’s portfolio invested in the stock 1.46% | Change in the portfolio weight of the stock over the last 3 months 0.19% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 18/119 (+5) |
Aditya Birla Sun Life Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.9340% | Percentage of the fund’s portfolio invested in the stock 1.07% | Change in the portfolio weight of the stock over the last 3 months 0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 32/91 (-5) |
Aditya Birla Sun Life Pure Value Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.3473% | Percentage of the fund’s portfolio invested in the stock 2.47% | Change in the portfolio weight of the stock over the last 3 months 0.17% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 7/86 (+2) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
Cash Dividend
Ex DateEx DateSep 9, 2024
Dividend/Share
₹2.50
Ex DateEx Date
Sep 9, 2024
Past Dividends
Cash Dividend
Ex DateEx DateAug 4, 2023
Dividend/Share
₹1.50
Ex DateEx Date
Aug 4, 2023
Cash Dividend
Ex DateEx DateAug 5, 2021
Dividend/Share
₹2.50
Ex DateEx Date
Aug 5, 2021
Cash Dividend
Ex DateEx DateJul 24, 2020
Dividend/Share
₹2.00
Ex DateEx Date
Jul 24, 2020
Cash Dividend
Ex DateEx DateAug 22, 2019
Dividend/Share
₹12.00
Ex DateEx Date
Aug 22, 2019
Cash Dividend
Ex DateEx DateJul 19, 2019
Dividend/Share
₹3.00
Ex DateEx Date
Jul 19, 2019
Strides Pharma Science has fixed 09 September 2024 as record date for final dividend of Rs 2.50 per share. Powered by Capital Market - Live
The good manufacturing practices (GMP) inspection was conducted from 1 April to 5 April 2024. The USFDA has determined that the inspection classification of this facility is voluntary action indicated (VAI). Strides Alathur facility caters to the U.S. and other regulated markets. The facility manufactures tablets & capsules and supports several current and future products for the US markets. Strides remains committed to the highest standards of compliance and will continue to focus on manufacturing high-quality pharmaceutical products for the Global markets, the company stated in exchange filing. Strides Pharma Science is engaged in develops and manufactures a wide range of IP-led niche pharmaceutical products. The company reported a consolidated net profit of Rs 70.20 crore in Q1 FY25 as against a net loss of Rs 7.11 crore posted in Q1 FY24. Revenue from operations stood at Rs 1,087.50 crore in the quarter ended June 2024, registering a growth of 16.93% YoY. The scrip declined 1.27% to Rs 1,297 on the BSE. Powered by Capital Market - Live
Strides Alathur, a wholly owned subsidiary of Strides Pharma Science (Strides) has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its formulations facility at Alathur, Chennai thereby successfully concluding the Good Manufacturing Practices (GMP) inspection conducted between April 1-5, 2024. USFDA has determined that the inspection classification of this facility is 'Voluntary Action Indicated' (VAI). Strides Alathur facility caters to the U.S. and Other Regulated Markets. The facility manufactures tablets & capsules and supports several current and future products for the US markets.Powered by Capital Market - Live
Strides Pharma, as a part of Group entites optimization exercises has liquidated its US unit by the relevant regulatory authorities of New Jersey. Altima Innovations Inc. was a non-operative entity so, its turnover for FY 2024 was NIL. The net worth of the company for FY ended 31 March 2024 was $6,620 (equivalent to approximately Rs 551,909). Strides Pharma Science is engaged in develops and manufactures a wide range of IP-led niche pharmaceutical products. The company reported a consolidated net profit of Rs 70.20 crore in Q1 FY25 as against a net loss of Rs 7.11 crore posted in Q1 FY24. Revenue from operations stood at Rs 1,087.50 crore in the quarter ended June 2024, registering a growth of 16.93% YoY. Shares of Strides Pharma Science hit 52-week high of Rs 1,298.50 in today's intraday session. Powered by Capital Market - Live
Strides Pharma Science announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 10 September 2024 .Powered by Capital Market - Live
Strides Pharma Science announces acquisition of balance stake in Strides Global Consumer Healthcare, UK
![](https://pocket-image-cache.com/direct?url=http://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg)
Strides Arcolab International (SAIL UK), a wholly owned subsidiary of Strides Pharma Science in UK, proposes to acquire balance stake in Strides Global Consumer Healthcare (Consumer UK) from the existing Investor. Consumer UK is an IP holding entity and is into the business of sale and distribution of pharmaceutical and other over-the-counter consumer health care products, through its subsidiaries in US and India. SAIL UK is currently holding 19% stake in Consumer UK. As at 31 March 2024, carrying value of this investment in the books of SAIL UK is NIL. SAIL UK is acquiring the balance 81% stake from the existing Investor at GBP One. Strides Group has assessed the business opportunity and would like to strengthen its existing portfolio with the CHC Brands which have good recall value. Strides can leverage its relationship with wholesalers in the US and other geographies and advance this business in various territories like US, UK and MENA.Powered by Capital Market - Live
![](https://i.ytimg.com/vi/zccLIw_zbTM/hqdefault.jpg?sqp=-oaymwEiCKgBEF5IWvKriqkDFQgBFQAAAAAYASUAAMhCPQCAokN4AQ==&rs=AOn4CLB4XMkhLh1RyDVt2n0Wql4OqFOZZg)
Strides Pharma reports profit of Rs 68.3 crore in Q1, revenue up 16%
![](https://pocket-image-cache.com/direct?url=http://bsmedia.business-standard.com/_media/bs/img/article/2023-09/25/thumb/featurecrop/400X400/1695645277-3128.jpg)
Strides Pharma Science allots 41,500 equity shares under ESOP
![](https://pocket-image-cache.com/direct?url=http://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg)
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 10.24%, vs industry avg of 9.21%
Decreasing Market Share
Over the last 5 years, market share decreased from 1.12% to 1.1%